WATERTOWN, Mass., June 17, 2026
Triveni Bio, a clinical-stage biotechnology company developing innovative antibody therapies for immunological and inflammatory diseases, has announced the successful completion of a $65 million Series C financing round to accelerate the clinical development of its next-generation pipeline and support the company’s next phase of growth. The financing was co-led by Ascenta Capital and Janus Henderson Investors, with significant participation from Deep Track Capital and existing investors. The new funding will primarily support the expansion of clinical studies for TRIV-573, a first-in-class bispecific antibody designed to address the underlying causes of atopic dermatitis by simultaneously targeting KLK5/7 and IL-13, two key drivers of skin barrier dysfunction and inflammation. The investment represents a major milestone for the company as it advances innovative precision medicine approaches aimed at transforming treatment options for patients living with chronic inflammatory skin disorders.
Series C Financing Supports Expanded Clinical Development
The newly secured capital will enable Triveni Bio to significantly broaden the scope of its clinical development strategy for TRIV-573, including the initiation of a larger Phase 2 proof-of-concept clinical trial in atopic dermatitis expected to begin later this year. The company believes that addressing both inflammation and skin barrier dysfunction simultaneously could offer a differentiated therapeutic approach compared to currently available treatments. By expanding the clinical program, Triveni aims to generate robust efficacy and safety data that could further validate the therapeutic potential of its dual-targeting antibody platform. Company executives noted that the financing provides the resources needed to investigate additional applications of kallikrein 5/7 biology across a range of barrier-related inflammatory diseases while continuing to advance precision medicine strategies based on genetic and mechanistic insights.
TRIV-573 Targets the Root Causes of Atopic Dermatitis
TRIV-573 is a half-life extended, second-generation bispecific antibody engineered to combine inhibition of KLK5/7, enzymes associated with skin barrier breakdown, with potent blockade of IL-13, a key inflammatory cytokine involved in atopic dermatitis pathogenesis. This dual mechanism is designed to address both structural and inflammatory aspects of disease progression, potentially offering a more comprehensive treatment approach. The financing announcement follows the recent initiation of first-in-human clinical studies for TRIV-573, marking a significant advancement in the program’s development.
Advertisement
Triveni believes that targeting the underlying biological mechanisms responsible for skin barrier dysfunction may provide meaningful benefits for patients who continue to experience symptoms despite existing therapies. The company’s approach reflects a growing trend within immunology and dermatology toward developing highly targeted biologics capable of delivering improved efficacy and long-term disease control.
Strategic Growth Strengthens Triveni Bio’s Position in Immunology
The financing also supports broader corporate expansion initiatives and strengthens Triveni Bio’s position within the competitive immunology and inflammation landscape. As part of the transaction, Evan Rachlin, M.D., Co-Founder and Managing Partner of Ascenta Capital, has joined the company’s Board of Directors, bringing extensive experience in biotechnology investment and clinical development. The funding follows a period of strong momentum for the company, including continued advancement of its lead programs and growing recognition of its leadership team.
Triveni’s broader pipeline includes TRIV-509, a monoclonal antibody targeting kallikrein 5 and 7 that is currently being evaluated in an ongoing Phase 2 clinical trial, with data expected later this year. By combining innovative antibody engineering with genetics-informed drug development, the company aims to establish early clinical proof-of-concept and accelerate the delivery of transformative therapies for patients with immune-mediated diseases. The successful financing round underscores investor confidence in Triveni’s scientific strategy, clinical programs, and long-term growth potential.
Source: Triveni Bio press release
